Mon Plaisir 23
10 articles with Synchron
Synchron Receives Green Light From FDA to Begin Breakthrough Trial of Implantable Brain Computer Interface in US
Synchron, a venture-backed brain data transfer company, announced that the U.S. Food and Drug Administration has approved its Investigational Device Exemption application for its flagship product, the StentrodeTM motor neuroprosthesis.
6/9/2021Things are warming up quickly this summer for life sciences investors. Here’s who’s coming in hot with cash this week.
Synchron Secures $40M in Series B led by Khosla Ventures to Launch U.S. Clinical Trials of Minimally Invasive Brain Computer Interface
Synchron, a brain interface platform company , today announced that the company has secured $40M in a eries B round of financing led by Silicon Valley venture capital firm Khosla Ventures.
Stentrode is the only implantable brain-computer interface that does not require open brain surgery and is currently in clinical trials
Synchron Inc. today announced the first successful clinical implantation of the Stentrode®, a minimally-invasive neural interface technology, a component of the Synchron Brain-Computer Interface.
Synchron Initiates First-ever Clinical Trial to Evaluate Thought-to-Text™ Brain-Computer Interface Technology in Patients with Severe Paralysis
Royal Melbourne Hospital study evaluates ability of minimally-invasive Stentrode™ neural interface technology in combination with BrainOS™ to restore communication in patients with severe paralysis due to stroke, motor neuron disease, ALS and spinal cord Injury
Study Published in Nature Biomed Shows Promise for Patients with Neurological Conditions including Parkinson's disease, Depression and Epilepsy
Synchron Inc., a company developing minimally invasive neural interface technology, today announced data demonstrating the feasibility of minimally-invasive techniques to enable focal brain stimulation has been published in the journal Nature Biomedical Engineering